Apnimed Inc. raised $192 million [3] in an upsized initial public offering that priced shares at $16 each on Thursday night.
The funding is critical for the biotech company as it moves toward the regulatory approval and commercial launch of Oxnimbi, an oral medication designed to treat obstructive sleep apnea.
The company, which trades under the ticker APMD on the Nasdaq, offered 12 million shares [1]. This represents a 20 percent increase over its original offering size. The $16 per share price [2] marked the top of the company's expected range.
Shares of Apnimed made their market debut on Friday, July 31, 2026. Following the pricing, the stock rose 6.3 percent [4] during its first day of trading.
Apnimed is a late-stage biotech company focusing on therapeutics for sleep apnea. The proceeds from the IPO will be used to fund the regulatory process for Oxnimbi, which seeks to provide a non-mechanical alternative to traditional treatments like CPAP machines.
While some early reports suggested a higher opening price, market data from Yahoo Finance and MarketWatch confirmed the 6.3 percent increase based on the $16 pricing [4].
“Apnimed raised $192 million in an upsized initial public offering”
The successful upsizing of the IPO indicates strong investor appetite for non-invasive sleep-apnea treatments. By securing nearly $200 million, Apnimed has the capital necessary to navigate the final stages of the FDA regulatory pipeline, potentially shifting the standard of care from mechanical devices to pharmaceutical intervention.
